Fluticasone furoate/umeclidinium bromide/vilanterol

Irenic Sends Letter to Theravance Biopharma Regarding the Urgent Need for a Governance Overhaul, Capital Return and Strategic Review

Retrieved on: 
Monday, February 27, 2023
Asset Management, Professional Services, Finance, Biotechnology, Trust, GSK, Collection, Appendix, Directorate of Research and Civil Affairs, Letter, Growth, Tax, Pershing Square Capital Management, Sale, Fluticasone furoate/umeclidinium bromide/vilanterol, Security (finance), Pharmaceutical industry, Management, Holding company, Risk management, Recycling, Revefenacin, Research

We invested in Theravance because we believe the Company is worth substantially more than its current market value.

Key Points: 
  • We invested in Theravance because we believe the Company is worth substantially more than its current market value.
  • Investors have substantial concerns with Theravance’s capital allocation, approach to executive compensation and operating costs, and management’s choice of ultimate strategic direction.
  • We have also proposed entering into a formal cooperation agreement in order to assist in unlocking Theravance’s value and improving governance and oversight.
  • Such rights include the right to call special meetings…”14
    To date, the Company has not committed to any of these steps.

Royalty Pharma Announces Expansion of Senior Leadership Team

Retrieved on: 
Thursday, December 15, 2022
Hematological Cancer Research Investment and Education Act, Fluticasone furoate/umeclidinium bromide/vilanterol, Vertex, Republican State Leadership Committee, Sale, Human capital, Natalizumab, AbbVie, Investment, Research, Senior, Publication, Royalty Pharma, EDGAR, Management, Ivacaftor

NEW YORK, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the expansion of its senior leadership team.

Key Points: 
  • NEW YORK, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the expansion of its senior leadership team.
  • This expansion highlights Royalty Pharma’s success in developing a talented, diverse and experienced leadership team responsible for formulating and executing on its mission to accelerate innovation and transform patient lives.
  • Brienne has been a key member of the Research & Investments team since joining Royalty Pharma in 2014.
  • Alessandra joined Royalty Pharma in 2020 and is responsible for overseeing Royalty Pharma’s human resource planning, professional development and performance management.

Innoviva Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam (SUL-DUR)

Retrieved on: 
Wednesday, November 30, 2022
FDA, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, Result, Infection, GSK, Incidence, Skin, Financial condition report, Communication, BLI, Nephrotoxicity, Food, Pneumonia, Safety, Colistin, Therapy, ABC, Distributive shock, Kidney failure, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Mortality, Agency, Analysis, Priority review, Hospital-acquired pneumonia, MD, Disease, Multiplicity of infection, Security (finance), NDA, Subclinical infection, Bloodstream infections, Time-invariant system, Blood pressure, Septic, II, Angiotensin, Fluticasone furoate/umeclidinium bromide/vilanterol, Data analysis, Coronavirus, Priority, PDUFA, FDA, Sulbactam, Pharmaceutical industry, Vaccine

The Agency is currently planning to hold an advisory committee meeting to discuss this application.

Key Points: 
  • The Agency is currently planning to hold an advisory committee meeting to discuss this application.
  • SUL-DUR also exhibited a favorable safety profile with statistically significant reduction in nephrotoxicity.
  • Carbapenem-resistant and multidrug-resistant Acinetobacter infections are an urgent and emergent threat due to increasing rates of resistance and few viable treatment options.
  • Our focused and dedicated team looks forward to continuing to work with the FDA throughout the priority review process.

Innoviva Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Wednesday, November 9, 2022
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Income, Private Securities Litigation Reform Act, Infectious Diseases Society of America, 2021 Essex County Council election, Distributive shock, Data analysis, Method, Investment, Royalty Pharma, U.S. Securities and Exchange Commission, Multiplicity of infection, Risk, Communication, Angiotensin, Financial condition report, Sale, Fluticasone furoate/umeclidinium bromide/vilanterol, Therapy, TRC, Share repurchase, NASDAQ, II, Coronavirus, Goal, Septic, Infection, Securities Exchange Act of 1934, GSK, Company, Program, Growth, Analysis, Result, Ownership, Security (finance), Blood pressure, Acquisition, Cryptocurrency, Pharmaceutical industry, Entasis

Innoviva, Inc. (NASDAQ: INVA) (Innoviva and the Company), a diversified holding company with a portfolio of royalties and other healthcare assets, today reported financial results for the third quarter ended September 30, 2022.

Key Points: 
  • Innoviva, Inc. (NASDAQ: INVA) (Innoviva and the Company), a diversified holding company with a portfolio of royalties and other healthcare assets, today reported financial results for the third quarter ended September 30, 2022.
  • Increase in fair values of equity and long-term investments of $0.1 million in the third quarter of 2022 was mainly due to the volatility in the capital markets.
  • Net cash and cash equivalents totaled $300.8 million, and royalty and product sale receivables totaled $72.3 million as of September 30, 2022.
  • ANORO ELLIPTA global net sales decreased by 15% compared to third quarter of 2021 mainly due to pricing pressures and foreign currency changes."

Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at IDWEEK 2022

Retrieved on: 
Wednesday, October 19, 2022
Doctor of Pharmacy, GSK, PDR, Mortality, Infectious Diseases Society of America, Institute, II, Test, XDR, ELF, Poster, Infection, Philippe Ciais, Therapy, Septic, Blood pressure, Private Securities Litigation Reform Act, Company, Medical microbiology, Incidence, GLOBE, Clinical trial, Colistin, Fluticasone furoate/umeclidinium bromide/vilanterol, Population, Diversified Specialty Institute Holdings, Inc., Probability, Multidrug-resistant bacteria, PTA, Multiplicity of infection, Special access program, United, Authorization, Nephrotoxicity, Data analysis, PPK, Angiotensin, Note, SEC, ABC, Patient, Distributive shock, Nasdaq, Sulbactam, Acquisition, MD, Doctor of Philosophy, BLI, Safety, Plasma, Forward-looking statement, Gram, Pharmaceutical industry, Vaccine, Risk management, Antibiotics, Pseudomonas, Entasis, FIDSA

Results showed that ABC isolates from patients in ATTACK were highly antibiotic-resistant, but >95% susceptible to SUL-DUR.

Key Points: 
  • Results showed that ABC isolates from patients in ATTACK were highly antibiotic-resistant, but >95% susceptible to SUL-DUR.
  • This study evaluated PPK in 373 subjects, including 110 patients who received SUL-DUR and underwent PK sampling in the pivotal Phase 3 ATTACK trial.
  • In addition to the oral presentations, three poster presentations highlighted additional SUL-DUR and ATTACK trial details and results.
  • All Entasis IDWeek 2022 presentations will be made available on the Entasis website https://www.entasistx.com/our-science/presentations-by-event.

Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Announces Data on SUL-DUR to be Presented at IDWeek 2022

Retrieved on: 
Wednesday, October 12, 2022
Angiotensin, Infection, Philippe Ciais, GSK, Note, SEC, Therapy, Septic, Fluticasone furoate/umeclidinium bromide/vilanterol, ABC, Patient, Kirkbi AG v Ritvik Holdings Inc, Blood pressure, Distributive shock, Infectious Diseases Society of America, Entasis, Nasdaq, II, Private Securities Litigation Reform Act, Company, Multidrug-resistant bacteria, Acquisition, Multiplicity of infection, United, 2021 Essex County Council election, GLOBE, Forward-looking statement, Gram, Pharmaceutical industry, Pseudomonas

Innoviva is a diversified holding company with a portfolio of royalties and innovative healthcare investments and assets.

Key Points: 
  • Innoviva is a diversified holding company with a portfolio of royalties and innovative healthcare investments and assets.
  • Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR/BREO ELLIPTA and ANORO ELLIPTA.
  • Forward-looking statements should not be relied upon as representing the Companys views as of any date subsequent to the date hereof.
  • Trademark reference:Innovivaand theInnovivalogo are registered trademarks or trademarks ofInnoviva, Inc.or its affiliates inthe United Statesand/or other countries.

Innoviva to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

Retrieved on: 
Thursday, September 8, 2022
Biotechnology, General Health, Other Health, Health, Pharmaceutical, Philippe Ciais, II, Morgan, Hilltop Holdings Inc., Multiplicity of infection, Fluticasone furoate/umeclidinium bromide/vilanterol, Angiotensin, GSK, Distributive shock, Investor relations, Infection, Conference, Nasdaq, Blood pressure, Multidrug-resistant bacteria, Acquisition, Septic, Pharmaceutical industry

Innoviva, Inc. (Nasdaq: INVA) (Innoviva), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Wednesday, September 14th at 11:10 a.m. Eastern Time.

Key Points: 
  • Innoviva, Inc. (Nasdaq: INVA) (Innoviva), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Wednesday, September 14th at 11:10 a.m. Eastern Time.
  • Innoviva is a diversified holding company with a portfolio of royalties and innovative healthcare investments and assets.
  • Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR/BREO ELLIPTA and ANORO ELLIPTA.
  • ANORO, RELVAR, BREO, TRELEGY and ELLIPTA are trademarks of the GSK group of companies.

Innoviva Completes Acquisition of La Jolla Pharmaceutical

Retrieved on: 
Monday, August 22, 2022
Biotechnology, General Health, Other Health, Health, Pharmaceutical, Security (finance), Philippe Ciais, II, Securities Exchange Act of 1934, Tax, Nasdaq, Multiplicity of infection, Exercise, Fluticasone furoate/umeclidinium bromide/vilanterol, Angiotensin, GSK, Coronavirus, Result, Distributive shock, Physician, Septic, Infection, Data analysis, U.S. Securities and Exchange Commission, Hospital, Goal, Blood pressure, Communication, Financial condition report, Analysis, Private Securities Litigation Reform Act, Acquisition, Patient, Pharmaceutical industry, Risk management, Entasis

Today, following the consummation of the tender offer, Innoviva successfully completed its acquisition of La Jolla, which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases.

Key Points: 
  • Today, following the consummation of the tender offer, Innoviva successfully completed its acquisition of La Jolla, which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases.
  • The acquisition of La Jolla strengthens our footprint in the hospital and infectious disease spaces by adding a robust portfolio of marketed products and an excellent team, said Pavel Raifeld, Chief Executive Officer of Innoviva.
  • All conditions of the offer were satisfied and Innoviva completed its acquisition of all issued and outstanding equity securities of La Jolla for the Offer Price.
  • As a result of the acquisition, La Jolla became a wholly-owned subsidiary of Innoviva and the companys common stock will be delisted from the Nasdaq Global Market.

Innoviva Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Wednesday, July 27, 2022
Biotechnology, Pharmaceutical, Health, Goal, Result, Income, Acquisition, Investment, U.S. Securities and Exchange Commission, Royalty Pharma, Private Securities Litigation Reform Act, Ownership, Securities Exchange Act of 1934, Infection, Financial condition report, Therapy, NASDAQ, Data analysis, GSK, Company, Security (finance), Coronavirus, Nasdaq, Fluticasone furoate/umeclidinium bromide/vilanterol, TRC, Analysis, Communication, Cryptocurrency, Retail, Pharmaceutical industry, Bank, Entasis

Innoviva, Inc. (NASDAQ: INVA) (Innoviva and the Company), a diversified holding company with a portfolio of royalties and a growing portfolio of healthcare assets in infectious disease and other areas of high unmet need, today reported financial results for the second quarter ended June 30, 2022.

Key Points: 
  • Innoviva, Inc. (NASDAQ: INVA) (Innoviva and the Company), a diversified holding company with a portfolio of royalties and a growing portfolio of healthcare assets in infectious disease and other areas of high unmet need, today reported financial results for the second quarter ended June 30, 2022.
  • Decrease in fair values of equity and long-term investments of $58.6 million in the second quarter of 2022 was mainly due to the volatility in the capital markets.
  • Second Quarter and Recent Corporate Updates:
    During the second quarter of 2022, the Companys wholly owned subsidiary, Innoviva Strategic Opportunities LLC, announced the purchase of all the issued and outstanding equity securities of Entasis Therapeutics not already owned by Innoviva and its affiliates for $2.20 per share for a consideration of $42.4 million.
  • Subsequent to the close of the second quarter of 2022, the Companys wholly owned subsidiary, Innoviva Strategic Opportunities LLC, entered into a definitive merger agreement to acquire La Jolla Pharmaceutical Company (Nasdaq: LJPC).

Royalty Pharma Agrees to Acquire Royalty Interest in TRELEGY ELLIPTA From Theravance and Innoviva for $1.31 Billion and Potential Milestones of $300 Million

Retrieved on: 
Wednesday, July 13, 2022
Orthostatic hypotension, Achievement, Goal, SEC, Interest, GSK, Sale, EDGAR, U.S. Securities and Exchange Commission, LLC, Acquisition, EBITDA, Multiple system atrophy, AbbVie, Investment, COPD, Maintenance, GAAP, Patient, Terminology, Ageing, GLOBE, Union, Blood pressure, Private Securities Litigation Reform Act, Adjustment, Nasdaq, Forward-looking statement, Asthma, Royalty Pharma, Publication, Communication, Bromide, Quality of life, Growth, Research, Forecasting, Chronic obstructive pulmonary disease, Armin Maiwald, Music, Pharmaceutical industry, Fine chemical, Bank, Security (finance), Bookkeeping, Elexacaftor/tezacaftor/ivacaftor, Derivative, Fluticasone furoate/umeclidinium bromide/vilanterol

In 2021, Trelegy generated sales of $1.68 billion, an increase of 57% at constant exchange rates versus the prior year.

Key Points: 
  • In 2021, Trelegy generated sales of $1.68 billion, an increase of 57% at constant exchange rates versus the prior year.
  • We are excited to acquire this royalty from Theravance and Innoviva, said Pablo Legorreta, Royalty Pharmas founder and Chief Executive Officer.
  • Royalty Pharma is acquiring from Theravance and Innoviva all of the equity interests in Theravance Respiratory Company, LLC, which is entitled to an upward tiering royalty of 6.5% to 10% on annual worldwide Trelegy sales, payable by GSK.
  • In exchange, Royalty Pharma will receive a low- to mid-single digit royalty on worldwide sales of ampreloxetine.